EP3812771A1 - Method for full course detection of c-reactive protein and corresponding kit - Google Patents

Method for full course detection of c-reactive protein and corresponding kit Download PDF

Info

Publication number
EP3812771A1
EP3812771A1 EP19823488.2A EP19823488A EP3812771A1 EP 3812771 A1 EP3812771 A1 EP 3812771A1 EP 19823488 A EP19823488 A EP 19823488A EP 3812771 A1 EP3812771 A1 EP 3812771A1
Authority
EP
European Patent Office
Prior art keywords
solution
antibody
citric acid
reagent
reactive protein
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
EP19823488.2A
Other languages
German (de)
French (fr)
Other versions
EP3812771A4 (en
EP3812771B1 (en
Inventor
Zimin CHEN
Junhui XIONG
Weiling XU
Zuxing WENG
Long Wang
Xiaohong ZHENG
Xudong Sun
Shengxiang Ge
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Xiamen Innodx Biotech Co Ltd
Xiamen University
Original Assignee
Xiamen Innodx Biotech Co Ltd
Xiamen University
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Xiamen Innodx Biotech Co Ltd, Xiamen University filed Critical Xiamen Innodx Biotech Co Ltd
Publication of EP3812771A1 publication Critical patent/EP3812771A1/en
Publication of EP3812771A4 publication Critical patent/EP3812771A4/en
Application granted granted Critical
Publication of EP3812771B1 publication Critical patent/EP3812771B1/en
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/543—Immunoassay; Biospecific binding assay; Materials therefor with an insoluble carrier for immobilising immunochemicals
    • G01N33/54393—Improving reaction conditions or stability, e.g. by coating or irradiation of surface, by reduction of non-specific binding, by promotion of specific binding
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/577—Immunoassay; Biospecific binding assay; Materials therefor involving monoclonal antibodies binding reaction mechanisms characterised by the use of monoclonal antibodies; monoclonal antibodies per se are classified with their corresponding antigens
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N21/00—Investigating or analysing materials by the use of optical means, i.e. using sub-millimetre waves, infrared, visible or ultraviolet light
    • G01N21/75—Systems in which material is subjected to a chemical reaction, the progress or the result of the reaction being investigated
    • G01N21/76—Chemiluminescence; Bioluminescence
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/531—Production of immunochemical test materials
    • G01N33/532—Production of labelled immunochemicals
    • G01N33/533—Production of labelled immunochemicals with fluorescent label
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/531—Production of immunochemical test materials
    • G01N33/532—Production of labelled immunochemicals
    • G01N33/535—Production of labelled immunochemicals with enzyme label or co-enzymes, co-factors, enzyme inhibitors or enzyme substrates
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/543—Immunoassay; Biospecific binding assay; Materials therefor with an insoluble carrier for immobilising immunochemicals
    • G01N33/54313—Immunoassay; Biospecific binding assay; Materials therefor with an insoluble carrier for immobilising immunochemicals the carrier being characterised by its particulate form
    • G01N33/54326—Magnetic particles
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/46—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans from vertebrates
    • G01N2333/47—Assays involving proteins of known structure or function as defined in the subgroups
    • G01N2333/4701—Details
    • G01N2333/4737—C-reactive protein

Definitions

  • the invention belongs to the technical field of chemiluminescence immunoassays, and specifically relates to a method for full-range detection of C-reactive protein and a corresponding kit.
  • C-Reactive protein is an acute phase reaction protein discovered by Tillet and Francis in 1930 that can react with Streptococcus pneumoniae C polysaccharide in the presence of Ca 2+ to form a complex; serum CRP is synthesized by hepatocytes under the stimulation of IL-6, IL-2 and TNF, and inflammatory local macrophages are also produced in small amounts.
  • CRP has a molecular weight of about 115KD and consists of five identical unglycosylated polypeptide subunits, each subunit contains 204 amino acids, these subunits are connected by non-covalent bonds to form a cyclic pentamer, and with an interchain disulfide bond, this pentameric protein has remarkable heat resistance and protein degradation resistance.
  • CRP is widely distributed in the body. In addition to blood, it can be detected in pleural fluid, ascites, pericardial fluid, and joint fluid.
  • CRP is an important acute reaction protein. It starts to increase at 6-8h after the occurrence of bacterial infection and reaches a peak at 24-48h. After the infection is eliminated, its content drops sharply and returns to normal within a week.
  • CRP is mainly used as a first-choice indicator to identify bacterial or viral infections, as well as to monitor disease changes and postoperative infections, to dynamically observe the efficacy of antibiotics, to guide and monitor treatments and the like.
  • CRP is also related to cardiovascular disease, coronary heart disease, and acute coronary syndrome, in which the level of CRP in patients is often significantly elevated, and the degree of the elevated level is significantly correlated to the degree of coronary artery obstruction, the occurrence and prognosis of the end-event of coronary heart disease, and congestive heart failure.
  • CRP is also an independent predictor of atrial fibrillation, and there is a certain correlation between serum CRP concentration and hypertension. The systolic and diastolic blood pressure levels of hypertensive patients increase with the increase of serum CRP concentration.
  • CRP detection method on the market mainly include hypersensitive CRP (hsCRP) detection, conventional CRP detection, and full-range CRP detection.
  • Hypersensitive CRP detection is mainly used to diagnose and predict the occurrence and development of cardiovascular events
  • conventional CRP detection is mainly used for bacterial infection, various inflammatory processes, tissue necrosis and tissue damage (such as post-operative damage), as well as screening, monitoring, disease evaluation and efficacy judgment during recovery period.
  • Early conventional CRP detection methods are mainly based on immuno-scattering turbidity or immuno-transmitting turbidity methods, with a detection capacity of more than 5 mg/L, but they are difficult to predict the risk of cardiovascular disease due to the lack of high sensitivity.
  • hypersensitive CRP detection for low concentrations is called hypersensitive CRP detection.
  • some detection methods can cover the detection linearity of hypersensitivity and full-range CRP at one time, such as chemiluminescence detection methods and immunofluorescence detection methods.
  • the line width of detection can reach 0.02-100mg/L.
  • the full-range CRP detection methods usually use the addition of competing free antibodies.
  • US Patent Application Publication No. US 2014/0017712 A1 mentions the use of adding a free monoclonal antibody or an antibody that can compete with coating or labeling.
  • such a method increases difficulty in operations such as reagent stability.
  • Chinese Patent Publication No. CN105988003A discloses a method in which the purpose of full-range detection is achieved by using alkali neutralization after acid destruction, but it is still not stable and convenient. Therefore, there still exists a need in the art to improve the method of the full-range CRP detection to realize a full-range CRP detection method in a stable and convenient detection mode.
  • the purpose of the present invention is to overcome the defects of the prior art and provide a stable and convenient method for full-range detection of C-reactive protein as well as a corresponding kit.
  • the present invention provides a kit for full-range detection of C-reactive protein, which comprises:
  • the present invention provides a kit for full-range detection of C-reactive protein, which comprises:
  • the pH of the citric acid solution is adjusted by disodium hydrogen phosphate dodecahydrate; preferably, the pH of the citric acid solution is 3.0-3.5; and more preferably, the pH of the citric acid solution is 3.2, 3.3, 3.4 or 3.5.
  • the concentration of the citric acid is 0.5 mol/L.
  • the pre-excitation solution is 1% (w/v) hydrogen peroxide solution
  • the excitation solution is 1 mol/L sodium hydroxide solution
  • the first antibody is 10C11
  • the second antibody is 14D9-2.
  • the present invention provides a method for full-range detection of C-reactive protein, which is performed using the kit of the present invention, and which comprises:
  • the present invention provides a use of a citric acid solution as a sample treatment solution in manufacture of a kit for full-range detection of C-reactive protein.
  • the present invention provides a kit for full-range detection of C-reactive protein (direct chemiluminescence, that is, magnetic particle-chemiluminescence method), which comprises the following components:
  • the luminescence mechanism of acridine compounds is: in an alkaline hydrogen peroxide solution, the molecule of acridine compound is attacked by hydrogen peroxide ions to form an unstable peroxy compound, which decomposes into CO2 and electronically excited N-methyl-acridone, when it returns to its ground state, it emits a photon with a maximum emission wavelength of 430 nm.
  • Surfactants such as Triton X-100, Tween-20, CTAC (hexadecyltrimethylammonium chloride, a cationic surfactant) can enhance luminescence.
  • the pH of the R1 reagent is adjusted by disodium hydrogen phosphate dodecahydrate.
  • the pH of the citric acid solution is adjusted by disodium hydrogen phosphate dodecahydrate.
  • the pH of the citric acid solution is 3.0-3.5, and more preferably, the pH of the citric acid solution is 3.2, 3.3, 3.4 or 3.5.
  • the concentration of the citric acid is 0.5 mol/L.
  • the M reagent contains 0.05% Tween-20 and 10% sucrose.
  • the pre-excitation solution is a 1% (w/v) hydrogen peroxide solution.
  • the excitation solution is 1 mol/L sodium hydroxide solution.
  • the present invention provides a kit for full-range detection of C-reactive protein (enzymatic chemiluminescence, namely horseradish peroxidase or alkaline phosphatase plate-type chemiluminescence), which comprises the following components:
  • Detection an automatic chemiluminescence analyzer (purchased from: Yantai Addcare Biotechnology Co., Ltd.) is used for reading the luminescence values.
  • first antibody and second antibody are both monoclonal antibodies that can specifically react with C-reactive protein.
  • the sample treatment solution is a 0.5 M citric acid solution with a pH of 3 to 3.5.
  • the pH of the sample treatment solution is adjusted by disodium hydrogen phosphate dodecahydrate.
  • the pH of the citric acid solution is adjusted by disodium hydrogen phosphate dodecahydrate.
  • the pH of the citric acid solution is 3.0-3.5, and more preferably, the pH of the citric acid solution is 3.2, 3.3, 3.4 or 3.5.
  • the concentration of the citric acid is 0.5 mol/L.
  • the flat-bottomed chemiluminescent plate coated with the first antibody comprises 5-8% calf serum and 0.02% sodium azide.
  • the color developing solution A is hydrogen peroxide
  • the color developing solution B is o-phenylenediamine
  • the color developing solution is a commercially available reagent.
  • the content is directly determined by an automatic chemiluminescence analyzer.
  • the reagents were of analytical grade, and unless otherwise specified, they were purchased from Xiamen Xilong Chemical Co., Ltd.
  • the kit for full-range detection of C-reactive protein (direct chemiluminescence, that is, magnetic particle chemiluminescence method) of the present invention comprises the following components:
  • the detection method using the above-mentioned kit for full-range detection of C-reactive protein comprised the following steps:
  • kits for full-range detection of C-reactive protein comprised the following components:
  • Detection an automatic chemiluminescence analyzer (purchased from: Yantai Addcare Biotechnology Co., Ltd.) was used for reading the luminescence values.
  • the above-mentioned first antibody and second antibody were monoclonal antibodies that could specifically react with C-reactive protein.
  • the first antibody was 10C11 and the second antibody was 14D9-2, both of which were purchased from Xiamen Innovax Biotech CO., Ltd.
  • the detection method using the above-mentioned kit for full-range detection of C-reactive protein comprised the following steps:
  • 0.1M citric acid and 0.1M glycine of different pH values were selected respectively as treatment solution, and added to the enzyme immunoassay system (the pH range was 2-6) to evaluate the gradiently diluted C-reactive protein antigen.
  • the relative OD values were shown in Tables 1 and 2 below.
  • Table 1 and Table 2 showed the detection results of the traced antigen of the full-range detection of C-reactive protein in the enzyme immunoassay system when the treatment solution was 0.1M citric acid with different pH values (adjusted to different pH values with disodium hydrogen phosphate dodecahydrate) and the treatment solution was 0.1M glycine with different pH values.
  • the results showed that there was an obvious trend in the detection between pH 3-4, while other pH ranges were not ideal. It could be seen from Tables 1 and 2 that when the range of pH 3-4 was selected as the treatment pH of the treatment solution, the sample detection exhibited a tend from high to low, which was better than other pH ranges.
  • the line width of the enzyme immunoassay system was not sufficient for full-range detection, so it was considered that the optimal pH range was 3-4 for chemiluminescence platform exploration, and citric acid was used for subsequent experiments.
  • citric acid concentration citric acid concentration of 0.1M, 0.5M, 1M
  • pH range pH3 and pH3.5, pH4
  • the citric acid solutions with different molar concentrations and pH 3-4 were selected as the treatment solution and added to the chemiluminescence detection system (i.e., magnetic particle chemiluminescence platform) to evaluate the gradiently diluted C-reactive protein antigen.
  • the gradiently diluted C-reactive protein antigen was treated, and the magnetic particle chemiluminescence platform or the enzymatic horseradish peroxidase chemiluminescence platform was used for detection to obtain the detection results, and the obtained results were made into standard curves. Then, the relative luminescence intensities of the 18 clinical samples collected (from Xiamen Zhongshan affiliated Hospital and Xijing Hospital) were separately shown in Table 3 and Table 4 below.
  • Table 3 Correlation of the influence of citric acid treatment solution with different pH and different concentration on the detection of C-reactive protein (magnetic particle chemiluminescence system) Citric acid concentration (mol/L) 0.1 0.5 1 pH value 3 3.5 4 3 3.5 4 3 3.5 4 Serum serial number of Zhong shan Hospital Background value (mg/L) Detection value (mg/L) 1257 46.70 58.17 50.68 19.67 38.70 49.77 96.64 65.72 73.63 163.59 1203 54.30 67.65 62.15 25.76 37.36 57.59 98.96 95.94 44.42 319.43 1444 170.00 106.50 120.46 37.40 87.46 137.30 189.87 273.05 209.85 79.81 1315 183.00 144.27 146.56 44.94 140.15 181.43 257.77 373.53 470.72 342.03 1432 136.00 78.22 89
  • Tables 3 and 4 showed that when three pH ranges of 3, 3.5 and 4 were fixed and different citric acid concentrations (0.1M, 0.5M and 1M) were used, the luminescent platform was used to detect the traced antigen of the full-range C-reactive protein and evaluate 18 samples. It was found that the citric acid with concentration of 0.5M and pH 3-3.5 showed better results. It could be seen from Table 3 that under the above concentration and pH, the correlation between serums was relative better between pH 3 to 3.5; 0.5M citric acid was preferred, the fluctuation was relatively smaller between pH 3 to 3.5 for 0.5M citric acid, and thus it was considered relatively stable.
  • 0.5M citric acid was selected to further optimize and refine the pH concentration (pH 2.8-4).
  • 0.5M citric acid of different pH was used as the treatment solution to treat the gradiently diluted C-reactive protein antigen, and the magnetic particle chemiluminescence platform or the enzymatic horseradish peroxidase chemiluminescence platform was used for detection to obtain the detection results; and then the results were made into standard curves.
  • the collected 18 clinical samples were then detected, and the detection results were shown in Table 5 and Table 6.
  • Tables 5 and 6 showed that when the optimal citric acid concentration previously explored was used, the pH concentration was carefully explored, disodium hydrogen phosphate dodecahydrate was selected to adjust different pH values (including pH 2.8 to 4), and the luminescence platform was used to detect the traced antigen of full-range C-reactive protein. It was found that the test samples of pH (3.0-3.5) showed better correlation, in which the magnetic particle chemiluminescence platform was the best at pH 3.4, and showed the best linear detection result.
  • the pH was in the range of 3.0 to 3.5
  • the C-reactive protein single serum had the linear correlation r 2 of above 0.96
  • the final preferred condition was 0.5M citric acid with pH (3.4)
  • the correlation in detection of 18 serum samples was above 0.97.
  • the enzymatic horseradish peroxidase luminescence platform showed the best linear detection results at pH 3.2.
  • the correlation of 15 serum samples was above 0.959.
  • the two reagents could meet the market demands (0.02-100mg/L), and the two reagents showed equivalent performance in evaluation of sample correlation.

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Biomedical Technology (AREA)
  • Hematology (AREA)
  • Molecular Biology (AREA)
  • Urology & Nephrology (AREA)
  • Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Analytical Chemistry (AREA)
  • General Physics & Mathematics (AREA)
  • General Health & Medical Sciences (AREA)
  • Biochemistry (AREA)
  • Cell Biology (AREA)
  • Medicinal Chemistry (AREA)
  • Food Science & Technology (AREA)
  • Microbiology (AREA)
  • Biotechnology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Plasma & Fusion (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Investigating Or Analysing Materials By The Use Of Chemical Reactions (AREA)

Abstract

The invention provides a kit for full-range detection of C-reactive protein based on chemiluminescence immunoassay and a method for full-range detection of C-reactive protein. The kit comprises an R1 reagent, an M reagent, an R2 reagent, a pre-excitation solution and an excitation solution. The R1 reagent, that is a sample treatment solution, is a 0.5M citric acid solution (pH 3.0-3.5, which is adjusted by disodium hydrogen phosphate dodecahydrate). The present invention also provides a kit for full-range detection of C-reactive protein, which comprises a flat-bottomed plate-type chemiluminescence plate coated with a first antibody, a sample treatment solution, a second antibody labeled with horseradish peroxidase (HRP) or alkaline phosphatase (AP), a color developing solution. The invention also provides a method for full-range detection of C-reactive protein using the kit. Both the first antibody and the second antibody are monoclonal antibodies that can specifically react with C-reactive protein.

Description

    Technical Field
  • The invention belongs to the technical field of chemiluminescence immunoassays, and specifically relates to a method for full-range detection of C-reactive protein and a corresponding kit.
    • Background
  • C-Reactive protein (CRP) is an acute phase reaction protein discovered by Tillet and Francis in 1930 that can react with Streptococcus pneumoniae C polysaccharide in the presence of Ca2+ to form a complex; serum CRP is synthesized by hepatocytes under the stimulation of IL-6, IL-2 and TNF, and inflammatory local macrophages are also produced in small amounts. CRP has a molecular weight of about 115KD and consists of five identical unglycosylated polypeptide subunits, each subunit contains 204 amino acids, these subunits are connected by non-covalent bonds to form a cyclic pentamer, and with an interchain disulfide bond, this pentameric protein has remarkable heat resistance and protein degradation resistance.
  • CRP is widely distributed in the body. In addition to blood, it can be detected in pleural fluid, ascites, pericardial fluid, and joint fluid.
  • CRP is an important acute reaction protein. It starts to increase at 6-8h after the occurrence of bacterial infection and reaches a peak at 24-48h. After the infection is eliminated, its content drops sharply and returns to normal within a week.
  • The clinical application of CRP is mainly used as a first-choice indicator to identify bacterial or viral infections, as well as to monitor disease changes and postoperative infections, to dynamically observe the efficacy of antibiotics, to guide and monitor treatments and the like. CRP is also related to cardiovascular disease, coronary heart disease, and acute coronary syndrome, in which the level of CRP in patients is often significantly elevated, and the degree of the elevated level is significantly correlated to the degree of coronary artery obstruction, the occurrence and prognosis of the end-event of coronary heart disease, and congestive heart failure. In addition, CRP is also an independent predictor of atrial fibrillation, and there is a certain correlation between serum CRP concentration and hypertension. The systolic and diastolic blood pressure levels of hypertensive patients increase with the increase of serum CRP concentration.
  • At present, CRP detection method on the market mainly include hypersensitive CRP (hsCRP) detection, conventional CRP detection, and full-range CRP detection. Hypersensitive CRP detection is mainly used to diagnose and predict the occurrence and development of cardiovascular events, while conventional CRP detection is mainly used for bacterial infection, various inflammatory processes, tissue necrosis and tissue damage (such as post-operative damage), as well as screening, monitoring, disease evaluation and efficacy judgment during recovery period. Early conventional CRP detection methods are mainly based on immuno-scattering turbidity or immuno-transmitting turbidity methods, with a detection capacity of more than 5 mg/L, but they are difficult to predict the risk of cardiovascular disease due to the lack of high sensitivity. Subsequent research and development provide an immune enhancement turbidimetric method, which analysis sensitivity is greatly improved, the lower limit of detection can reach 0.02mg/L. This hypersensitive CRP detection for low concentrations is called hypersensitive CRP detection. With the continuous innovation and improvement of technology, some detection methods can cover the detection linearity of hypersensitivity and full-range CRP at one time, such as chemiluminescence detection methods and immunofluorescence detection methods. The line width of detection can reach 0.02-100mg/L.
  • At present, the full-range CRP detection methods usually use the addition of competing free antibodies. For example, US Patent Application Publication No. US 2014/0017712 A1 mentions the use of adding a free monoclonal antibody or an antibody that can compete with coating or labeling. However, such a method increases difficulty in operations such as reagent stability. Chinese Patent Publication No. CN105988003A discloses a method in which the purpose of full-range detection is achieved by using alkali neutralization after acid destruction, but it is still not stable and convenient. Therefore, there still exists a need in the art to improve the method of the full-range CRP detection to realize a full-range CRP detection method in a stable and convenient detection mode.
    • Contents of the Invention
  • The purpose of the present invention is to overcome the defects of the prior art and provide a stable and convenient method for full-range detection of C-reactive protein as well as a corresponding kit.
  • The technical solution of the present invention is as follows:
    In one aspect, the present invention provides a kit for full-range detection of C-reactive protein, which comprises:
    • an M reagent, comprising 0.5∼1mg/mL magnetic particles coated with a first antibody, 0.04∼0.06% (w/v) surfactant (the surfactant is optionally Tween-20), and 8∼12% (w/v) sucrose, its solvent is a phosphate buffer with pH=7.0∼8.0; wherein the coating amount of the first antibody is 5∼20µg/mg magnetic particles;
    • an R1 reagent, that is a sample treatment solution, which is a citric acid solution with a concentration of 0.1∼1M, pH=3.0∼4.0;
    • an R2 reagent, comprising acridinium ester coated with a secondary antibody, 0.5-1% casein and 0.5-1% bovine serum albumin, its solvent is phosphate buffer with pH=7.0-8.0, wherein the coating amount of the secondary antibody is 0.3-0.9µg/µg acridinium ester;
    • a pre-excitation solution and an excitation solution;
    • wherein the first antibody and the second antibody are both monoclonal antibodies that can specifically react with C-reactive protein, and the first antibody and the second antibody are directed to different epitopes.
  • In another aspect, the present invention provides a kit for full-range detection of C-reactive protein, which comprises:
    • a flat-bottomed plate-type chemiluminescence plate coated with a first antibody, which comprises a plate-type luminescence plate (optionally, 96-well, 384-well or other plate-type luminescence plate), wherein the coating amount of the first antibody is 100∼500ng/well (optionally 500ng/well), the coating buffer is a phosphate buffer with pH=7.0∼8.0, the blocking solution is 50mM phosphate buffer with pH of 7.2-7.4 comprising 5-8% (w/v) blocking serum or blocking protein (the blocking serum is optionally calf serum) and 0.02% (w/v) sodium azide;
    • a sample treatment solution, which is a citric acid solution with a concentration of 0.1∼1M, pH=3∼4;
    • a labeling enzyme solution, comprising a secondary antibody labeled with horseradish peroxidase or alkaline phosphatase, and having a labeling amount that 1 mg/mL of the secondary antibody is labeled with horseradish peroxidase or alkaline phosphatase in the same proportion;
    • a color developing solution: when the labeling enzyme is horseradish peroxidase, the color developing solution comprises a color developing solution A and a color developing solution B, and the color developing solution A is hydrogen peroxide (optionally, the formula of the color developing solution A: 13.6g of sodium acetate, 1.6g of citric acid, 0.3ml of 30% hydrogen peroxide, formulated with distilled water to 500ml), the color developing solution B is o-phenylenediamine (optionally, the formula of the color developing solution B: 0.2 g of disodium ethylenediaminetetraacetate, 0.95g of citric acid, 50ml of glycerol, 9.15g of tetramethylbenzidine, formulated with distilled water to 500ml); when the labeling enzyme is alkaline phosphatase, the color developing solution is a commercially available reagent;
    • wherein the first antibody and the second antibody are both monoclonal antibodies that can specifically react with C-reactive protein, and the first antibody and the second antibody are directed to different epitopes.
  • In some embodiments, the pH of the citric acid solution is adjusted by disodium hydrogen phosphate dodecahydrate; preferably, the pH of the citric acid solution is 3.0-3.5; and more preferably, the pH of the citric acid solution is 3.2, 3.3, 3.4 or 3.5.
  • In other embodiments, the concentration of the citric acid is 0.5 mol/L.
  • In some embodiments, the pre-excitation solution is 1% (w/v) hydrogen peroxide solution, the excitation solution is 1 mol/L sodium hydroxide solution, the first antibody is 10C11, and the second antibody is 14D9-2.
  • In still other embodiments, the method for preparing the M reagent comprises: the first antibody and the magnetic particles are mixed in 2-morpholineethanesulfonic acid buffer with pH=5.0∼6.0, coated at 25-37°C for 1-3h, added with 0. 1%∼0.5% (w/v) bovine serum albumin phosphate buffer with pH=8.0∼9.0 to perform termination for 1∼3h, the coated magnetic particles are separated and dispersed in a phosphate buffer with pH=7.0∼8.0, then added with 0.04∼0.06% (w/v) surfactant (the surfactant is optionally Tween-20; in one embodiment, the surfactant is 0.05% (w/v) Tween-20) and 8∼12% (w/v) sucrose (optionally, 10% (w/v) sucrose) to obtain the M reagent;
    the method for preparing the R2 reagent comprises: the second antibody and acridinium ester are mixed in a phosphate buffer with pH=8.0∼9.0, coated at 25-37°C for 1∼3h, and then added with a Tris buffer comprising 0.1%∼0.5% (w/v) bovine serum albumin and having pH=8.0∼9.0 to perform termination for 1∼3h so as to obtain a stock solution, and the stock solution is diluted with a phosphate buffer having pH=7.0∼8.0 to 1:100∼500 to obtain the R2 reagent.
  • In other embodiments, the method for preparing the luminescent plate coating source comprises: the coated first antibody is diluted with a phosphate buffer having pH=7.0-8.0 as coating buffer to 100-500ng/well (optionally, 500ng/well), added to the luminescent plate, 100µL per well, incubated at 37°C for 2h or 4°C overnight, the coating buffer is poured out, 200µL of the blocking solution comprising 5-8% (w/v) calf serum and 0.02% (w/v) sodium azide is used for incubation at 37°C for 2h, the liquid in the wells is poured out, the plate is dried and sealed under vacuum with aluminum film, and stored in a dry place at 4°C;
    the method for preparing the labeling enzyme solution comprises: the second antibody and horseradish peroxidase or alkaline phosphatase in ratio of 1:1 are mixed and labeled and dialyzed in a carbonate buffer with pH=9.6, and the dialysis buffer is replaced every 4 hours and replaced for three times, the enzyme-labeled secondary antibody is collected to be a stock solution, and then the stock solution is diluted with a commercially available enzyme diluent to 1:500 to obtain the labeling enzyme solution.
  • In yet another aspect, the present invention provides a method for full-range detection of C-reactive protein, which is performed using the kit of the present invention, and which comprises:
    1. (1) 20µL of a sample is taken and added to 100µL of the R1 reagent to treat the sample;
    2. (2) 50µL of the M reagent is then added and incubated together for 15min;
    3. (3) after step (2), washing is performed with a phosphate buffer comprising 0.05∼0.08% (w/v) Tween-20, then 50 µL of the R2 reagent is added and incubated for 10 minutes;
    4. (4) after step (3), washing is performed with a phosphate buffer comprising 0.05∼0.08% (w/v) Tween-20, and 100 µL of the pre-excitation solution is added to perform pre-excitation;
    5. (5) the pre-excitation solution is removed, 100 µL of the excitation solution is then added to perform excitation and detection.
  • In another aspect, the present invention provides a use of a citric acid solution as a sample treatment solution in manufacture of a kit for full-range detection of C-reactive protein.
  • In some embodiments, the citric acid solution is a citric acid solution with a concentration of 0.1∼1M, pH=3∼4; preferably, the pH of the citric acid solution is adjusted by disodium hydrogen phosphate dodecahydrate, more preferably, the pH of the citric acid solution is 3.0-3.5, more preferably, the pH of the citric acid solution is 3.2, 3.3, 3.4 or 3.5.
  • In one aspect, the present invention provides a kit for full-range detection of C-reactive protein (direct chemiluminescence, that is, magnetic particle-chemiluminescence method), which comprises the following components:
    • an M reagent, comprising 0.5∼1mg/mL magnetic particles coated with a first antibody, 0.04∼0.06% (w/v) surfactant (the surfactant is optionally Tween-20), and 8∼12% (w/v) sucrose, its solvent is a phosphate buffer with pH=7.0∼8.0; wherein the coating amount of the first antibody is 5∼20µg/mg magnetic particles;
    • an R1 reagent, that is a sample treatment solution, which is a citric acid solution with a concentration of 0.1∼1M, pH=3.0∼4.0;
    • an R2 reagent, comprising acridinium ester coated with a secondary antibody, 0.5-1% casein and 0.5-1% bovine serum albumin, its solvent is phosphate buffer with pH=7.0∼8.0, wherein the coating amount of the secondary antibody is 0.3-0.9µg/µg acridinium ester;
    • a pre-excitation solution and an excitation solution;
    • wherein the first antibody and the second antibody are both monoclonal antibodies that can specifically react with C-reactive protein, and the first antibody and the second antibody are directed to different epitopes.
  • The luminescence mechanism of acridine compounds is: in an alkaline hydrogen peroxide solution, the molecule of acridine compound is attacked by hydrogen peroxide ions to form an unstable peroxy compound, which decomposes into CO2 and electronically excited N-methyl-acridone, when it returns to its ground state, it emits a photon with a maximum emission wavelength of 430 nm. Surfactants such as Triton X-100, Tween-20, CTAC (hexadecyltrimethylammonium chloride, a cationic surfactant) can enhance luminescence.
  • In a preferred embodiment of the present invention, the R1 reagent is 0.5M citric acid solution, pH=3∼3.5.
  • Further preferably, the pH of the R1 reagent is adjusted by disodium hydrogen phosphate dodecahydrate.
  • In one embodiment, the pH of the citric acid solution is adjusted by disodium hydrogen phosphate dodecahydrate. Preferably, the pH of the citric acid solution is 3.0-3.5, and more preferably, the pH of the citric acid solution is 3.2, 3.3, 3.4 or 3.5.
  • In yet another embodiment, the concentration of the citric acid is 0.5 mol/L.
  • Further preferably, the M reagent contains 0.05% Tween-20 and 10% sucrose.
  • Further preferably, the method for preparing the M reagent comprises: the first antibody and the magnetic particles are mixed in 2-morpholineethanesulfonic acid buffer with pH=5.0∼6.0, coated at 25-37°C for 1-3h, added with 0.1%∼0.5% (w/v) bovine serum albumin phosphate buffer with pH=8.0∼9.0 to terminate the coating for 1∼3h, the coated magnetic particles are separated and dispersed in a phosphate buffer with pH=7.0∼8.0, then added with Tween-20 and sucrose to obtain the M reagent.
  • Further preferably, the method for preparing the R2 reagent comprises: the second antibody and acridinium ester are mixed in a phosphate buffer with pH=8.0∼9.0, coated at 25-37°C for 1∼3h, and then added with a Tris buffer comprising 0.1%∼0.5% (w/v) bovine serum albumin and having pH=8.0∼9.0 to terminate the coating for 1∼3h so as to obtain a stock solution, and the stock solution is diluted with a phosphate buffer having pH=7.0∼8.0 to 1:100∼500 to obtain the R2 reagent.
  • Further preferably, the pre-excitation solution is a 1% (w/v) hydrogen peroxide solution.
  • Furthermore, the excitation solution is 1 mol/L sodium hydroxide solution.
  • In another aspect, the present invention provides a kit for full-range detection of C-reactive protein (enzymatic chemiluminescence, namely horseradish peroxidase or alkaline phosphatase plate-type chemiluminescence), which comprises the following components:
    • a flat-bottomed chemiluminescence plate coated with a first antibody, which comprises a plate-type luminescence plate (optionally, 96-well, 384-well or other plate-type luminescence plate), wherein the coating amount of the first antibody is 100∼500ng/well (optionally 500ng/well), the coating buffer is a phosphate buffer with pH=7.0∼8.0, the blocking solution is 50mM phosphate buffer with pH of 7.2-7.4 comprising 5-8% (w/v) blocking serum or blocking protein (the blocking serum is optionally calf serum) and 0.02% (w/v) sodium azide;
    • a sample treatment solution, which is a citric acid solution with a concentration of 0.1∼1M, pH=3∼4;
    • a labeling enzyme solution, comprising a secondary antibody labeled with horseradish peroxidase or alkaline phosphatase, and having a labeling amount that 1 mg/mL of the secondary antibody is labeled with horseradish peroxidase or alkaline phosphatase in the same proportion;
    • a color developing solution: when the labeling enzyme is horseradish peroxidase, the color developing solution comprises a color developing solution A and a color developing solution B, and the color developing solution A is hydrogen peroxide (13.6g of sodium acetate, 1.6g of citric acid, 0.3ml of 30% hydrogen peroxide, formulated with distilled water to 500ml), the color developing solution B is o-phenylenediamine (the formula of the color developing solution B: 0.2 g of disodium ethylenediaminetetraacetate, 0.95g of citric acid, 50ml of glycerol, 9.15g of tetramethylbenzidine, formulated with distilled water to 500ml); when the labeling enzyme is alkaline phosphatase, the color developing solution is a commercially available reagent (Art. No.: 180309-01, purchased from: Xiamen Boson Biotechnology Co., Ltd.).
  • Detection: an automatic chemiluminescence analyzer (purchased from: Yantai Addcare Biotechnology Co., Ltd.) is used for reading the luminescence values.
  • The above-mentioned first antibody and second antibody are both monoclonal antibodies that can specifically react with C-reactive protein.
  • In a preferred embodiment of the present invention, the sample treatment solution is a 0.5 M citric acid solution with a pH of 3 to 3.5.
  • Further preferably, the pH of the sample treatment solution is adjusted by disodium hydrogen phosphate dodecahydrate.
  • In one embodiment, the pH of the citric acid solution is adjusted by disodium hydrogen phosphate dodecahydrate. Preferably, the pH of the citric acid solution is 3.0-3.5, and more preferably, the pH of the citric acid solution is 3.2, 3.3, 3.4 or 3.5.
  • In yet another embodiment, the concentration of the citric acid is 0.5 mol/L.
  • Further preferably, the flat-bottomed chemiluminescent plate coated with the first antibody comprises 5-8% calf serum and 0.02% sodium azide.
  • Further preferably, the method for preparing the flat-bottomed chemiluminescent plate coated with the first antibody comprises: the coated first antibody is diluted with a phosphate buffer having pH=7.0-8.0 as coating buffer to 5µg/mL, i.e., 500ng/well, added to the luminescent plate, 100µL per well, incubated at 37°C for 2h or 4°C overnight, the coating buffer is poured out, 200µL of the blocking solution (5-8% (w/v) calf serum and 0.02% (w/v) sodium azide) is used for incubation at 37°C for 2h, the liquid in the wells is poured out, the plate is dried and sealed under vacuum with aluminum film, and stored in a dry place at 4°C.
  • Further preferably, the method for preparing the labeling enzyme solution comprises: the second antibody and horseradish peroxidase or alkaline phosphatase in ratio of 1:1 are mixed and labeled and dialyzed in a carbonate buffer with pH=9.6, and the dialysis buffer is replaced every 4 hours, for three times, the enzyme-labeled secondary antibody is collected to be the stock solution, and then the stock solution is diluted with a commercially available enzyme diluent to 1:500 to obtain the labeling enzyme solution.
  • Further preferably, when the labeling enzyme is horseradish peroxidase, the color developing solution A is hydrogen peroxide, and the color developing solution B is o-phenylenediamine; when the labeling enzyme is alkaline phosphatase, the color developing solution is a commercially available reagent.
  • Furthermore, the content is directly determined by an automatic chemiluminescence analyzer.
  • The beneficial effect of the present invention is that the detection range of the kit of the present invention can be 0.02mg/L to 100mg/L after a sample treatment solution (citric acid solution with a concentration of 0.1∼1M, pH=3∼4) is added in one step during the reaction process of the kit of the present invention, so that the kit can meet the requirements of full-range detection of C-reactive protein.
    • Brief Description of the Drawings
    • Figure 1 shows a paired dose-response curve, which is a curve of a calibrator for pairing detection. The left image represents the paired dose-response curve for 10C11-7D9, and the right image represents the paired dose-response curve for 10C11-14D9-2.
    • Figure 2 shows a correlation analysis of pairing detection results, which evaluates the correlation between samples and background values. The left image represents the correlation analysis of pairing detection results for 10C11-7D9, and the right image represents the correlation analysis of pairing detection results for 10C11-14D9-2.
    Detailed Embodiments of the Invention
  • The technical solution of the present invention is further illustrated and described below through specific embodiments.
  • The reagents were of analytical grade, and unless otherwise specified, they were purchased from Xiamen Xilong Chemical Co., Ltd.
  • In one embodiment, the kit for full-range detection of C-reactive protein (direct chemiluminescence, that is, magnetic particle chemiluminescence method) of the present invention comprises the following components:
    • an M reagent, comprising 0.8mg/mL magnetic particles coated with a first antibody, 0.05% Tween-20 and 10% sucrose, and its solvent was a phosphate buffer with pH=7.5, wherein the coating amount of the first antibody was 12 µg/µg magnetic particles, the magnetic particles were purchased from Thermo Fisher Scientific and were nano-scale superparamagnetic particles with Fe3O4 core. The method for preparing the M reagent comprised: the first antibody and magnetic particles were mixed in 2-morpholineethanesulfonic acid buffer with pH=5.5, coated at 32°C for 1∼3h, and added with a phosphate buffer solution comprising 0.3% bovine serum albumin and having pH=8.5 to terminate the coating for 2h, the coated magnetic particles were separated and dispersed in a phosphate buffer solution with pH=7.5, and then added with Tween-20 and sucrose to obtain the M reagent;
    • an R1 reagent, a citric acid solution with a concentration of 0.5M, pH=3.2, adjusted with disodium hydrogen phosphate dodecahydrate;
    • an R2 reagent, comprising acridinium ester coated with the secondary antibody, 0.8% casein and 0.8% bovine serum albumin, its solvent was a phosphate buffer with pH=7.5, and the coating amount of the secondary antibody was 12µg/µg acridinium ester. The method for preparing the R2 reagent comprised: the second antibody and acridinium ester were mixed in a phosphate buffer with pH=8.5, coated at 32°C for 1∼3h, added with a Tris buffer solution comprising 0.3% bovine serum albumin and having pH=8.5 to terminate the coating for 2h so as to obtain a stock solution; the stock solution was diluted with a phosphate buffer having pH=7.5 to 1:300 so as to obtain the R2 reagent;
    • pre-excitation solution, 1% (w/v) hydrogen peroxide solution;
    • exciting solution, 1mol/L sodium hydroxide solution;
    • the above-mentioned first antibody and second antibody were monoclonal antibodies that could specifically react with C-reactive protein. The first antibody was 10C11 and the second antibody was 14D9-2, both of which were purchased from Xiamen Innovax Biotech CO., Ltd.
  • The detection method using the above-mentioned kit for full-range detection of C-reactive protein comprised the following steps:
    1. (1) 20µL of a sample (the sample is a serum or a standard C-reactive protein for preparing antigen standard curve) was taken and added to 100µL of the R1 reagent to treat the sample;
    2. (2) 50µL of the M reagent was then added and incubated together for 15min;
    3. (3) after step (2), washing was performed with a phosphate buffer comprising 0.05% Tween-20, then 50 µL of the R2 reagent was added and incubated for 10min;
    4. (4) after step (3), washing was performed with a phosphate buffer comprising 0.05∼0.08% (w/v) Tween-20, and 100 µL of the pre-excitation solution is added to perform pre-excitation;
    5. (5) the pre-excitation solution is removed, 100 µL of the excitation solution is added to perform excitation and detection.
  • In another embodiment, the kit for full-range detection of C-reactive protein (enzymatic chemiluminescence, that is, horseradish peroxidase plate-type chemiluminescence) of the present invention comprised the following components:
    • a luminescent plate coating source, comprising a 96-well plate luminescent plate, in which the coating amount of the first antibody was 500ng/well, the coating buffer was a phosphate buffer with pH=7.5, and the blocking solution was 50 mM phosphate buffer with a pH of 7.3 comprising 6% calf serum and 0.02% sodium azide. The method for preparing the luminescent plate coating source comprised: the first antibody was diluted with phosphate buffer having pH=7.5 as coating buffer to 5µg/mL (i.e., 500ng/well), added to the luminescent plate, 100µL per well, incubated at 37°C for 2h or at 4°C overnight, the coating buffer was poured out, 200µL of the blocking solution comprising 6% calf serum and 0.02% sodium azide was used for incubation at 37°C for 2h, the liquid in the wells was poured out, the plate was dried and sealed under vacuum with aluminum film, and stored in a dry place at 4°C;
    • a sample treatment solution, which is a citric acid solution with a concentration of 0.5M, pH=3.2, adjusted with disodium hydrogen phosphate dodecahydrate;
    • a labeling enzyme solution, comprising a secondary antibody labeled with horseradish peroxidase or alkaline phosphatase, and having a labeling amount that 1 mg/mL of the secondary antibody was labeled with horseradish peroxidase and alkaline phosphatase in the same proportion. The method for preparing the labeling enzyme solution comprised: the second antibody and horseradish peroxidase or alkaline phosphatase in ratio of 1:1 were mixed and labeled and dialyzed in a carbonate buffer of pH=9.6, and the dialysis buffer was replaced once every 4 hours, for 3 times, the enzyme-labeled secondary antibody was collected to obtain a stock solution, and then the stock solution was diluted with a commercial enzyme diluent (Cat. No. ED-11, purchased from Beijing Wantai Biopharmaceutical Co., Ltd.) to 1:500 to obtain the labeling enzyme solution;
    • a color developing solution: when the labeling enzyme was horseradish peroxidase, the color developing solution A was hydrogen peroxide, and the color developing solution B was o-phenylenediamine; when the labeling enzyme was alkaline phosphatase, the color developing solution was a purchased reagent (purchased from: Xiamen Boson Biotechnology Co., Ltd.).
  • Detection: an automatic chemiluminescence analyzer (purchased from: Yantai Addcare Biotechnology Co., Ltd.) was used for reading the luminescence values.
  • The above-mentioned first antibody and second antibody were monoclonal antibodies that could specifically react with C-reactive protein. The first antibody was 10C11 and the second antibody was 14D9-2, both of which were purchased from Xiamen Innovax Biotech CO., Ltd.
  • The detection method using the above-mentioned kit for full-range detection of C-reactive protein comprised the following steps:
    1. (1) 20µL of a sample was taken and added to 100µL of the sample treatment solution to treat the sample;
    2. (2) then added to the luminescent plate coating source and incubated together at 37°C for 40min;
    3. (3) after step (2), washing was performed for 5 times with a phosphate buffer comprising 0.05% Tween-20, the luminescent plate was turned upside-down till dry, then 100 µL of labeling enzyme solution was added and incubated at 37°C for 40 min;
    4. (4) after step (3), washing was performed for 5 times with a phosphate buffer comprising 0.05% Tween-20, the luminescent plate was turn upside-down till dry; if the labeling enzyme was horseradish peroxidase, 50µL of the color developing solution A and 50µL of the color developing solution B were added, reacted at room temperature for 5min; if the labeling enzyme was alkaline phosphatase, 100µL of color developing solution (purchased from: Xiamen Boson Biotechnology Co., Ltd.) was added and reacted at room temperature for 5min; finally, the automatic chemiluminescence analyzer was used to perform detection and read the luminescence values.
    Examples Example 1
  • 0.1M citric acid and 0.1M glycine of different pH values were selected respectively as treatment solution, and added to the enzyme immunoassay system (the pH range was 2-6) to evaluate the gradiently diluted C-reactive protein antigen. The relative OD values were shown in Tables 1 and 2 below. Table 1: Effects of 0.1M citric acid treatment solutions with different pH values on the detection of C-reactive protein
    Concentration (mg/L) pH=2 pH=3 pH=4 pH=5 pH=6
    100.00 0.4090 1.4410 3.7590 0.7350 1.0130
    25.00 0.5760 1.3740 3.7620 1.0160 1.2900
    6.25 0.1510 0.8930 3.7590 1.3460 1.5250
    1.56 0.0430 0.3720 3.7760 2.4110 2.8010
    0.39 0.0120 0.0960 3.0050 1.5960 3.2060
    0.10 0.0060 0.0240 0.9480 0.8620 2.2130
    0.02 0.0100 0.0110 0.2560 0.0640 0.2760
    Table 2: Effects of 0.1M glycine treatment solutions with different pH values on the detection of C-reactive protein
    Concentration (mg/L) pH=2 pH=3 pH=4 pH=5 pH=6
    100 3.7910 3.7500 2.6820 3.2820 1.7660
    25 2.6980 3.5760 2.3680 2.9670 2.1690
    6.25 0.5270 3.0060 2.5510 3.2550 2.3350
    1.56 0.1100 0.6840 2.6910 3.3620 2.8260
    0.39 0.0330 0.1780 1.1610 1.7100 1.8980
    0.1 0.0190 0.0440 0.5440 0.7650 0.6870
    0.02 0.0140 0.0150 0.1090 0.1850 0.0880
  • Table 1 and Table 2 showed the detection results of the traced antigen of the full-range detection of C-reactive protein in the enzyme immunoassay system when the treatment solution was 0.1M citric acid with different pH values (adjusted to different pH values with disodium hydrogen phosphate dodecahydrate) and the treatment solution was 0.1M glycine with different pH values. The results showed that there was an obvious trend in the detection between pH 3-4, while other pH ranges were not ideal. It could be seen from Tables 1 and 2 that when the range of pH 3-4 was selected as the treatment pH of the treatment solution, the sample detection exhibited a tend from high to low, which was better than other pH ranges. However, the line width of the enzyme immunoassay system was not sufficient for full-range detection, so it was considered that the optimal pH range was 3-4 for chemiluminescence platform exploration, and citric acid was used for subsequent experiments.
    • Example 2
  • Based on Example 1, the improvement and adjustment of citric acid concentration (citric acid concentration of 0.1M, 0.5M, 1M) and pH range (pH3 and pH3.5, pH4) were carried out, the relative linear width of the enzyme immunoassay system was relatively narrow, and the preferred solution was adjusted on chemiluminescence platform. The citric acid solutions with different molar concentrations and pH 3-4 were selected as the treatment solution and added to the chemiluminescence detection system (i.e., magnetic particle chemiluminescence platform) to evaluate the gradiently diluted C-reactive protein antigen. By using citric acid with different pH and different concentration, the gradiently diluted C-reactive protein antigen was treated, and the magnetic particle chemiluminescence platform or the enzymatic horseradish peroxidase chemiluminescence platform was used for detection to obtain the detection results, and the obtained results were made into standard curves. Then, the relative luminescence intensities of the 18 clinical samples collected (from Xiamen Zhongshan Affiliated Hospital and Xijing Hospital) were separately shown in Table 3 and Table 4 below. Table 3: Correlation of the influence of citric acid treatment solution with different pH and different concentration on the detection of C-reactive protein (magnetic particle chemiluminescence system)
    Citric acid concentration (mol/L) 0.1 0.5 1
    pH value 3 3.5 4 3 3.5 4 3 3.5 4
    Serum serial number of Zhong shan Hospital Background value (mg/L) Detection value (mg/L)
    1257 46.70 58.17 50.68 19.67 38.70 49.77 96.64 65.72 73.63 163.59
    1203 54.30 67.65 62.15 25.76 37.36 57.59 98.96 95.94 44.42 319.43
    1444 170.00 106.50 120.46 37.40 87.46 137.30 189.87 273.05 209.85 79.81
    1315 183.00 144.27 146.56 44.94 140.15 181.43 257.77 373.53 470.72 342.03
    1432 136.00 78.22 89.66 22.38 76.33 102.71 132.89 182.84 200.50 88.86
    1333 110.00 99.11 100.68 45.29 62.90 109.99 186.08 165.51 65.75 186.25
    1478 70.30 46.69 56.99 10.28 41.24 47.21 83.52 65.98 132.74 152.31
    1233 62.30 53.84 60.32 16.85 44.19 54.97 102.16 88.10 104.26 154.66
    1207 84.80 97.89 75.66 17.15 79.43 69.73 113.89 107.25 120.61 91.72
    1210 40.10 43.45 43.21 10.23 29.06 36.09 71.60 46.09 63.54 67.85
    1231 36.90 60.52 59.45 45.53 37.01 49.67 99.61 77.69 17.84 193.95
    1338 33.70 39.83 39.97 6.90 30.62 35.97 69.69 47.56 5.99 124.40
    1223 24.20 30.60 32.36 3.34 23.25 31.46 82.90 40.27 6.61 72.51
    1230 29.00 28.35 32.70 12.25 22.82 26.86 60.01 38.28 27.95 106.24
    1349 16.80 19.46 24.65 8.17 15.58 19.75 56.57 29.44 12.92 88.97
    1317 12.10 16.12 20.92 12.24 12.03 16.52 37.35 20.29 16.66 40.57
    1316 5.40 9.94 6.74 12.49 6.26 7.82 19.74 18.29 23.27 2.77
    1324 9.10 10.52 11.43 17.12 8.79 7.84 24.26 13.17 19.98 39.97
    Serum serial number of Zhong shan Hospital Background value (Log10) Detection value (Log10)
    1257 1.67 1.76 1.70 1.29 1.59 1.70 1.99 1.82 1.87 2.21
    1203 1.73 1.83 1.79 1.41 1.57 1.76 2.00 1.98 1.65 2.50
    1444 2.23 2.03 2.08 1.57 1.94 2.14 2.28 2.44 2.32 1.90
    1315 2.26 2.16 2.17 1.65 2.15 2.26 2.41 2.57 2.67 2.53
    1432 2.13 1.89 1.95 1.35 1.88 2.01 2.12 2.26 2.30 1.95
    1333 2.04 2.00 2.00 1.66 1.80 2.04 2.27 2.22 1.82 2.27
    1478 1.85 1.67 1.76 1.01 1.62 1.67 1.92 1.82 2.12 2.18
    1233 1.79 1.73 1.78 1.23 1.65 1.74 2.01 1.94 2.02 2.19
    1207 1.93 1.99 1.88 1.23 1.90 1.84 2.06 2.03 2.08 1.96
    1210 1.60 1.64 1.64 1.01 1.46 1.56 1.85 1.66 1.80 1.83
    1231 1.57 1.78 1.77 1.66 1.57 1.70 2.00 1.89 1.25 2.29
    1338 1.53 1.60 1.60 0.84 1.49 1.56 1.84 1.68 0.78 2.09
    1223 1.38 1.49 1.51 0.52 1.37 1.50 1.92 1.61 0.82 1.86
    1230 1.46 1.45 1.51 1.09 1.36 1.43 1.78 1.58 1.45 2.03
    1349 1.23 1.29 1.39 0.91 1.19 1.30 1.75 1.47 1.11 1.95
    1317 1.08 1.21 1.32 1.09 1.08 1.22 1.57 1.31 1.22 1.61
    1316 0.73 1.00 0.83 1.10 0.80 0.89 1.30 1.26 1.37 0.44
    1324 0.96 1.02 1.06 1.23 0.94 0.89 1.38 1.12 1.30 1.60
    r2 0.9304 0.9586 0.2907 0.9692 0.9615 0.9179 0.9251 0.5942 0.4972
    Table 4: Correlation of the influence of citric acid treatment solution with different pH and different concentration on the detection of C-reactive protein (enzymatic horseradish peroxidase chemiluminescence system)
    Citric acid concentration (mol/L) 0.1 0.5 1
    pH value 3 3.5 4 3 3.5 4 3 3.5 4
    Serum serial number of Zhongshan Hospital Background value (mg/L) Detection value (mg/L)
    1242 20 27.77 139.53 37.45 37.13 17.22 140.83 82.22 92.16 9.14
    1351 5 34.19 163.47 20.06 13.03 3.15 53.52 25.86 34.85 5.10
    1402 3.8 15.56 89.20 21.63 9.55 3.51 37.49 24.61 31.38 1.56
    1417 25.8 59.31 289.25 30.77 54.35 15.76 221.95 73.38 110.76 7.75
    1408 33.2 59.31 348.65 43.69 66.34 24.84 136.92 133.23 151.15 10.03
    1341 38.1 76.55 501.37 37.72 71.94 34.57 68.66 159.38 352.94 10.32
    1255 45.7 64.17 234.53 42.15 83.93 39.37 137.79 195.34 231.96 11.19
    1247 55.6 51.16 142.44 23.93 91.89 27.36 121.47 97.02 82.81 11.30
    1276 62.3 82.81 302.86 22.94 94.97 55.71 92.95 206.66 386.77 12.87
    1365 65.4 64.67 406.95 34.06 113.07 47.36 129.91 303.71 240.53 12.23
    1404 140 104.87 405.49 87.16 209.22 73.61 132.60 239.11 264.62 15.46
    1246 13.2 27.49 125.45 27.00 19.99 5.67 125.97 54.08 60.48 9.04
    1239 14.6 42.23 125.20 21.44 20.84 8.52 130.21 52.57 123.92 6.15
    1382 133 85.53 592.49 70.10 155.30 90.13 100.33 424.02 506.85 19.91
    1393 136 83.84 444.01 32.82 211.47 69.50 92.66 163.08 187.86 18.68
    1484 70.3 59.54 970.42 102.66 105.58 43.79 85.37 421.22 383.87 21.00
    1277 18.4 32.57 91.97 56.87 29.44 12.78 168.98 110.16 115.56 8.94
    1493 67.7 72.98 336.93 307.01 104.80 59.61 74.96 393.77 340.69 17.50
    Serum serial number of Zhongshan Hospital Background value (Log10) Detection value (Log10)
    1242 1.30 1.44 2.14 1.57 1.57 1.24 2.15 1.91 1.96 0.96
    1351 0.70 1.53 2.21 1.30 1.11 0.50 1.73 1.41 1.54 0.71
    1402 0.58 1.19 1.95 1.34 0.98 0.54 1.57 1.39 1.50 0.19
    1417 1.41 1.77 2.46 1.49 1.74 1.20 2.35 1.87 2.04 0.89
    1408 1.52 1.77 2.54 1.64 1.82 1.40 2.14 2.12 2.18 1.00
    1341 1.58 1.88 2.70 1.58 1.86 1.54 1.84 2.20 2.55 1.01
    1255 1.66 1.81 2.37 1.62 1.92 1.60 2.14 2.29 2.37 1.05
    1247 1.75 1.71 2.15 1.38 1.96 1.44 2.08 1.99 1.92 1.05
    1276 1.79 1.92 2.48 1.36 1.98 1.75 1.97 2.32 2.59 1.11
    1365 1.82 1.81 2.61 1.53 2.05 1.68 2.11 2.48 2.38 1.09
    1404 2.15 2.02 2.61 1.94 2.32 1.87 2.12 2.38 2.42 1.19
    1246 1.12 1.44 2.10 1.43 1.30 0.75 2.10 1.73 1.78 0.96
    1239 1.16 1.63 2.10 1.33 1.32 0.93 2.11 1.72 2.09 0.79
    1382 2.12 1.93 2.77 1.85 2.19 1.95 2.00 2.63 2.70 1.30
    1393 2.13 1.92 2.65 1.52 2.33 1.84 1.97 2.21 2.27 1.27
    1484 1.85 1.77 2.99 2.01 2.02 1.64 1.93 2.62 2.58 1.32
    1277 1.26 1.51 1.96 1.75 1.47 1.11 2.23 2.04 2.06 0.95
    1493 1.83 1.86 2.53 2.49 2.02 1.78 1.87 2.60 2.53 1.24
    r2 0.7954 0.4898 0.2703 0.9759 0.9495 0.1002 0.8034 0.7264 0.8121
  • Tables 3 and 4 showed that when three pH ranges of 3, 3.5 and 4 were fixed and different citric acid concentrations (0.1M, 0.5M and 1M) were used, the luminescent platform was used to detect the traced antigen of the full-range C-reactive protein and evaluate 18 samples. It was found that the citric acid with concentration of 0.5M and pH 3-3.5 showed better results. It could be seen from Table 3 that under the above concentration and pH, the correlation between serums was relative better between pH 3 to 3.5; 0.5M citric acid was preferred, the fluctuation was relatively smaller between pH 3 to 3.5 for 0.5M citric acid, and thus it was considered relatively stable.
    • Example 3
  • 0.5M citric acid was selected to further optimize and refine the pH concentration (pH 2.8-4). 0.5M citric acid of different pH was used as the treatment solution to treat the gradiently diluted C-reactive protein antigen, and the magnetic particle chemiluminescence platform or the enzymatic horseradish peroxidase chemiluminescence platform was used for detection to obtain the detection results; and then the results were made into standard curves. The collected 18 clinical samples were then detected, and the detection results were shown in Table 5 and Table 6. Table 5 Correlation of the influence of 0.5M citric acid treatment solutions with different pH on the detection of C-reactive protein (magnetic particle chemiluminescence system)
    Citric acid concentration (mol/L) 0.5
    pH value 2.8 3.0 3.2 3.4 3.5 3.6 3.8 4
    Serum serial number of Zhong shan Hospital Backgroun d value (mg/L) Detection value (mg/L)
    1257 46.70 41.51 38.70 34.66 34.23 49.77 39.04 39.02 96.64
    1203 54.30 52.57 37.36 42.20 37.53 57.59 51.86 47.60 98.96
    1444 170.00 98.97 87.46 86.84 72.81 137.30 78.51 64.71 189.87
    1315 183.00 180.00 140.15 136.04 110.94 181.43 113.01 81.42 257.77
    1432 136.00 75.33 76.33 72.26 66.97 102.71 74.05 58.84 132.89
    1333 110.00 78.86 62.90 63.58 58.17 109.99 69.18 62.38 186.08
    1478 70.30 51.60 41.24 39.64 39.12 47.21 40.94 44.16 83.52
    1233 62.30 44.84 44.19 41.87 43.44 54.97 45.01 39.10 102.16
    1207 84.80 101.81 79.43 71.45 55.36 69.73 54.71 46.83 113.89
    1210 40.10 29.66 29.06 27.17 26.77 36.09 37.45 36.37 71.60
    1231 36.90 45.18 37.01 38.04 33.17 49.67 39.54 42.19 99.61
    1338 33.70 32.44 30.62 27.45 26.63 35.97 38.25 34.35 69.69
    1223 24.20 23.28 23.25 21.48 22.13 31.46 20.15 37.00 82.90
    1230 29.00 25.81 22.82 20.91 26.46 26.86 29.64 34.47 60.01
    1349 16.80 15.64 15.58 16.75 17.43 19.75 23.79 30.96 56.57
    1317 12.10 10.63 12.03 13.21 15.00 16.52 21.95 23.37 37.35
    1316 5.40 5.91 6.26 7.11 8.13 7.82 11.94 13.43 19.74
    1324 9.10 8.11 8.79 9.96 10.39 7.84 14.53 17.05 24.26
    Serum serial number of Zhong shan Hospital Backgroun d value (Log10) Detection value (Log10)
    1257 1.67 1.62 1.59 1.54 1.53 1.70 1.59 1.59 1.99
    1203 1.73 1.72 1.57 1.63 1.57 1.76 1.71 1.68 2.00
    1444 2.23 2.00 1.94 1.94 1.86 2.14 1.89 1.81 2.28
    1315 2.26 2.26 2.15 2.13 2.05 2.26 2.05 1.91 2.41
    1432 2.13 1.88 1.88 1.86 1.83 2.01 1.87 1.77 2.12
    1333 2.04 1.90 1.80 1.80 1.76 2.04 1.84 1.80 2.27
    1478 1.85 1.71 1.62 1.60 1.59 1.67 1.61 1.65 1.92
    1233 1.79 1.65 1.65 1.62 1.64 1.74 1.65 1.59 2.01
    1207 1.93 2.01 1.90 1.85 1.74 1.84 1.74 1.67 2.06
    1210 1.60 1.47 1.46 1.43 1.43 1.56 1.57 1.56 1.85
    1231 1.57 1.65 1.57 1.58 1.52 1.70 1.60 1.63 2.00
    1338 1.53 1.51 1.49 1.44 1.43 1.56 1.58 1.54 1.84
    1223 1.38 1.37 1.37 1.33 1.35 1.50 1.30 1.57 1.92
    1230 1.46 1.41 1.36 1.32 1.42 1.43 1.47 1.54 1.78
    1349 1.23 1.19 1.19 1.22 1.24 1.30 1.38 1.49 1.75
    1317 1.08 1.03 1.08 1.12 1.18 1.22 1.34 1.37 1.57
    1316 0.73 0.77 0.80 0.85 0.91 0.89 1.08 1.13 1.30
    1324 0.96 0.91 0.94 1.00 1.02 0.89 1.16 1.23 1.38
    r2 0.9547 0.9692 0.9672 0.9786 0.9615 0.9471 0.9319 0.9179
    Table 6: Correlation of the influence of 0.5M citric acid treatment solution with different pH on the detection of C-reactive protein (enzymatic horseradish peroxidase chemiluminescence system)
    Citric acid concentration (mol/L) 0.5
    pH value 2.8 3.0 3.2 3.4 3.5 3.6 3.8 4
    Serum serial number of Zhong shan Hospital Backgroun d value (mg/L) Detection value (mg/L)
    1445 170 17.65 65.14 122.17 118.01 101.83 133.13 87.17 28.26
    1449 140 18.45 58.83 120.32 138.13 139.69 137.80 113.82 22.61
    1283 114 13.50 33.13 74.65 125.50 87.12 111.72 150.29 29.15
    1238 114 18.20 53.46 94.57 157.07 130.74 136.98 174.20 28.40
    1465 73.1 15.85 31.78 59.66 115.18 104.39 119.16 136.63 23.71
    1366 65.4 8.13 23.87 45.86 83.41 54.86 58.97 86.38 22.05
    1303 58.8 9.23 24.63 55.07 88.79 57.88 79.32 52.87 12.73
    1487 52.2 5.90 15.02 33.21 73.56 58.32 83.29 105.08 30.43
    1345 42.3 3.41 10.48 18.21 33.29 38.14 37.83 65.16 28.49
    1454 33.2 3.67 13.92 25.27 54.27 38.88 43.03 57.80 36.47
    1461 25.8 2.74 9.24 20.37 37.56 28.74 50.86 69.94 32.99
    1394 18.8 3.07 11.64 20.62 42.19 26.63 33.52 82.36 33.42
    1470 9.2 1.70 4.39 8.60 14.50 15.27 17.11 32.14 41.04
    1407 8.1 0.39 1.94 7.01 8.82 6.54 7.64 10.36 37.76
    1370 5.9 0.36 1.89 4.58 11.98 6.72 6.71 6.75 27.83
    Serum serial number of Zhong shan Hospital Backgroun d value (Log10) Detection value (Log10)
    1445 2.23 1.25 1.81 2.09 2.07 2.01 2.12 1.94 1.45
    1449 2.15 1.27 1.77 2.08 2.14 2.15 2.14 2.06 1.35
    1283 2.06 1.13 1.52 1.87 2.10 1.94 2.05 2.18 1.46
    1238 2.06 1.26 1.73 1.98 2.20 2.12 2.14 2.24 1.45
    1465 1.86 1.20 1.50 1.78 2.06 2.02 2.08 2.14 1.37
    1366 1.82 0.91 1.38 1.66 1.92 1.74 1.77 1.94 1.34
    1303 1.77 0.97 1.39 1.74 1.95 1.76 1.90 1.72 1.10
    1487 1.72 0.77 1.18 1.52 1.87 1.77 1.92 2.02 1.48
    1345 1.63 0.53 1.02 1.26 1.52 1.58 1.58 1.81 1.45
    1454 1.52 0.56 1.14 1.40 1.73 1.59 1.63 1.76 1.56
    1461 1.41 0.44 0.97 1.31 1.57 1.46 1.71 1.84 1.52
    1394 1.27 0.49 1.07 1.31 1.63 1.43 1.53 1.92 1.52
    1470 0.96 0.23 0.64 0.93 1.16 1.18 1.23 1.51 1.61
    1407 0.91 -0.41 0.29 0.85 0.95 0.82 0.88 1.02 1.58
    1370 0.77 -0.44 0.28 0.66 1.08 0.83 0.83 0.83 1.44
    r2 0.9206 0.9468 0.9591 0.9154 0.9401 0.9204 0.7299 0.2197
  • Tables 5 and 6 showed that when the optimal citric acid concentration previously explored was used, the pH concentration was carefully explored, disodium hydrogen phosphate dodecahydrate was selected to adjust different pH values (including pH 2.8 to 4), and the luminescence platform was used to detect the traced antigen of full-range C-reactive protein. It was found that the test samples of pH (3.0-3.5) showed better correlation, in which the magnetic particle chemiluminescence platform was the best at pH 3.4, and showed the best linear detection result.
  • In the above pH range and in combination with the results in Table 5, the pH was in the range of 3.0 to 3.5, the C-reactive protein single serum had the linear correlation r2 of above 0.96, the final preferred condition was 0.5M citric acid with pH (3.4), and the correlation in detection of 18 serum samples was above 0.97. From the results in Table 6, the enzymatic horseradish peroxidase luminescence platform showed the best linear detection results at pH 3.2. The correlation of 15 serum samples was above 0.959.
    • Example 4
  • The optimized detection system was used to detect gradiently diluted C-reactive protein antigen to make a standard curve, then the collected 47 clinical samples were detected, their concentration values were calculated through the standard curve and subjected to the correlation evaluation against the clinical background values, and the results were shown in Table 7 below (magnetic particle chemiluminescence platform): Table 7
    Serum serial number of Zhongshan Hospital Background value (mg/L) Log10 Detection value (mg/L) Log10
    1 10.59 1.02 10.99 1.04
    2 16.95 1.23 14.88 1.17
    3 107.75 2.03 112.29 2.05
    4 23.77 1.38 16.99 1.23
    5 11.88 1.07 12.97 1.11
    6 37.34 1.57 27.23 1.44
    7 14.8 1.17 15.41 1.19
    8 65.23 1.81 71.81 1.86
    9 64.93 1.81 49.28 1.69
    10 135.45 2.13 225.39 2.35
    11 38.85 1.59 25.73 1.41
    12 81.04 1.91 102.13 2.01
    13 37.34 1.57 21.58 1.33
    14 15.4 1.19 11.87 1.07
    15 10.88 1.04 12.81 1.11
    16 15.09 1.18 16.10 1.21
    17 6.65 0.82 6.85 0.84
    18 9 0.95 8.20 0.91
    19 69.29 1.84 40.24 1.60
    20 85.55 1.93 90.29 1.96
    21 9.42 0.97 10.08 1.00
    22 14.11 1.15 15.54 1.19
    23 33 1.52 23.67 1.37
    24 50.97 1.71 35.66 1.55
    25 28.42 1.45 28.40 1.45
    Serum serial number of Xijing Hospital
    1 1.5 0.18 2.11 0.32
    2 1.32 0.12 2.29 0.36
    3 4.24 0.63 5.57 0.75
    4 0.285 -0.55 0.66 -0.18
    5 0.737 -0.13 1.18 0.07
    6 5.62 0.75 6.60 0.82
    7 3.63 0.56 4.65 0.67
    8 1.37 0.14 2.44 0.39
    9 1.39 0.14 2.03 0.31
    10 37 1.57 21.02 1.32
    11 1.4 0.15 2.49 0.40
    12 0.159 -0.80 0.34 -0.46
    13 2.87 0.46 3.94 0.60
    14 44.3 1.65 31.67 1.50
    15 45 1.65 26.10 1.42
    16 17.4 1.24 16.19 1.21
    17 60.1 1.78 30.51 1.48
    18 3.02 0.48 5.27 0.72
    19 0.665 -0.18 1.33 0.12
    20 15.4 1.19 12.34 1.09
    21 0.381 -0.42 0.93 -0.03
    22 1.81 0.26 2.87 0.46
  • Through correlation evaluation, the correlation equation of the two was y = 0.8151x + 0.2179, and the correlation coefficient r2 = 0.9692, indicating that the two had a good correlation.
  • The optimized detection system was used to detect gradiently diluted C-reactive protein antigen to make a standard curve, then the collected 73 clinical samples were detected, their concentration values were calculated through the standard curve and subjected to the correlation evaluation against the clinical background values, and the results were shown in Table 8 below (enzymatic horseradish peroxidase chemiluminescence platform): Table 8
    Serum serial number of Zhongshan Hospital Background value (mg/L) Log10 Detection value (mg/L) Log10
    1 20 1.30 32.42 1.51
    2 5 0.70 5.37 0.73
    3 3.8 0.58 5.90 0.77
    4 22.8 1.36 46.23 1.66
    5 25.8 1.41 40.60 1.61
    6 33.2 1.52 53.73 1.73
    7 38.1 1.58 67.42 1.83
    8 45.7 1.66 73.19 1.86
    9 62.3 1.79 89.68 1.95
    10 65.4 1.82 74.84 1.87
    11 140 2.15 155.47 2.19
    12 110 2.04 140.33 2.15
    13 13.2 1.12 12.42 1.09
    14 14.6 1.16 22.56 1.35
    15 133 2.12 176.93 2.25
    16 45 1.65 93.78 1.97
    17 65.4 1.82 111.15 2.05
    18 70.3 1.85 92.69 1.97
    19 18.4 1.26 27.67 1.44
    20 67.7 1.83 82.16 1.91
    21 170 2.23 203.55 2.31
    22 170 2.23 228.36 2.36
    23 140 2.15 216.73 2.34
    24 182 2.26 555.17 2.74
    25 41.7 1.62 60.82 1.78
    26 43.1 1.63 57.47 1.76
    27 33.2 1.52 44.20 1.65
    28 42.3 1.63 48.68 1.69
    29 31.3 1.50 42.16 1.62
    30 86.1 1.94 179.86 2.25
    31 58.8 1.77 100.40 2.00
    32 39.6 1.60 59.01 1.77
    33 21.8 1.34 46.29 1.67
    34 41.7 1.62 59.99 1.78
    35 33.3 1.52 73.34 1.87
    36 58.6 1.77 104.54 2.02
    37 57.8 1.76 76.28 1.88
    38 29 1.46 43.97 1.64
    39 39.6 1.60 32.97 1.52
    40 30.2 1.48 38.47 1.59
    Serum serial number of Xijing Hospital
    1 58.6 1.77 110.22 2.04
    2 26.3 1.42 28.64 1.46
    3 24.2 1.38 22.55 1.35
    4 5.6 0.75 7.98 0.90
    5 7 0.85 9.95 1.00
    6 9.1 0.96 10.88 1.04
    7 7.8 0.89 10.32 1.01
    8 6.9 0.84 7.85 0.89
    9 6.5 0.81 10.58 1.02
    10 12.1 1.08 19.77 1.30
    11 16.8 1.23 25.96 1.41
    12 42.3 1.63 50.42 1.70
    13 114 2.06 179.29 2.25
    14 6.9 0.84 5.40 0.73
    15 17.1 1.23 21.13 1.32
    16 58.6 1.77 102.90 2.01
    17 213 2.33 418.66 2.62
    18 20.3 1.31 35.05 1.54
    19 170 2.23 196.84 2.29
    20 140 2.15 187.56 2.27
    21 114 2.06 152.75 2.18
    22 114 2.06 144.88 2.16
    23 77.9 1.89 185.85 2.27
    24 73.1 1.86 97.58 1.99
    25 65.4 1.82 71.60 1.85
    26 58.8 1.77 81.52 1.91
    27 52.2 1.72 48.59 1.69
    28 33.2 1.52 34.49 1.54
    29 25.8 1.41 37.18 1.57
    30 18.8 1.27 30.58 1.49
    31 9.2 0.96 12.20 1.09
    32 8.1 0.91 7.77 0.89
    33 5.9 0.77 5.73 0.76
  • Through correlation evaluation, the correlation equation between the two was y = 1.056x + 0.0619, and the correlation coefficient r2 = 0.9506, indicating that the two had a good correlation.
    • Example 5
  • The optimized detection system and the reagents for acid-treatment and alkali-neutralization as mentioned in the patent application with publication number CN105988003A were used to detect the gradiently diluted C-reactive protein antigen so as to make standard curves, and then the collected 48 clinical samples were detected and their concentration values were calculated through the standard curves and subjected to the correlation evaluated against the clinical background values, the performance difference between the two was evaluated, and the results were shown in Figures 1 and 2 (magnetic particle chemiluminescence platform).
  • In comparison of line width of the traced antigen, the two reagents could meet the market demands (0.02-100mg/L), and the two reagents showed equivalent performance in evaluation of sample correlation.
  • It could be seen that the detection range of the kit of the present invention could reach 0.02 mg/L to 100 mg/L after the sample treatment solution (citric acid solution with a concentration of 0.1 to 1 M, pH=3 to 4) was added in one step in the reaction process of the kit of the present invention, so that the kit met the requirements of full-range detection of C-reactive protein.
  • The above are only preferred examples of the present invention, so the scope of implementation of the present invention cannot be limited accordingly. That is, equivalent changes and modifications made according to the scope of the present invention and the contents of the specification should still fall within the scope covered by the present invention.

Claims (10)

  1. A kit for full-range detection of C-reactive protein, which comprises:
    an M reagent, comprising 0.5∼1mg/mL magnetic particles coated with a first antibody, 0.04∼0.06% (w/v) surfactant (the surfactant is optionally Tween-20), and 8∼12% (w/v) sucrose, its solvent is a phosphate buffer with pH=7.0∼8.0; wherein the coating amount of the first antibody is 5∼20µg/mg magnetic particles;
    an R1 reagent, that is a sample treatment solution, which is a citric acid solution with a concentration of 0.1∼1M, pH=3.0∼4.0;
    an R2 reagent, comprising acridinium ester coated with a secondary antibody, 0.5-1% casein and 0.5-1% bovine serum albumin, its solvent is a phosphate buffer with pH=7.0-8.0, wherein the coating amount of the secondary antibody is 0.3-0.9µg/µg acridinium ester;
    a pre-excitation solution and an excitation solution;
    wherein the first antibody and the second antibody are both monoclonal antibodies that can specifically react with C-reactive protein, and the first antibody and the second antibody are directed to different epitopes.
  2. A kit for full-range detection of C-reactive protein, which comprises:
    a flat-bottomed plate-type chemiluminescence plate coated with a first antibody, which comprises a plate-type luminescence plate (optionally, 96-well, 384-well or other plate-type luminescence plate), wherein the coating amount of the first antibody is 100∼500ng/well (optionally 500ng/well), the coating buffer is a phosphate buffer with pH=7.0∼8.0, the blocking solution is 50mM phosphate buffer with pH of 7.2-7.4 comprising 5-8% (w/v) blocking serum or blocking protein (the blocking serum is optionally calf serum) and 0.02% (w/v) sodium azide;
    a sample treatment solution, which is a citric acid solution with a concentration of 0.1∼1M, pH=3∼4;
    a labeling enzyme solution, comprising a secondary antibody labeled with horseradish peroxidase or alkaline phosphatase, and having a labeling amount that 1 mg/mL of the secondary antibody is labeled with horseradish peroxidase or alkaline phosphatase in the same proportion;
    a color developing solution: when the labeling enzyme is horseradish peroxidase, the color developing solution comprises a color developing solution A and a color developing solution B, and the color developing solution A is hydrogen peroxide (optionally, the formula of the color developing solution A: 13.6g of sodium acetate, 1.6g of citric acid, 0.3ml of 30% hydrogen peroxide, formulated with distilled water to 500ml), the color developing solution B is o-phenylenediamine (optionally, the formula of the color developing solution B: 0.2 g of disodium ethylenediaminetetraacetate, 0.95g of citric acid, 50ml of glycerol, 9.15g of tetramethylbenzidine, formulated with distilled water to 500ml); when the labeling enzyme is alkaline phosphatase, the color developing solution is a commercially available reagent;
    wherein the first antibody and the second antibody are both monoclonal antibodies that can specifically react with C-reactive protein, and the first antibody and the second antibody are directed to different epitopes.
  3. The kit according to claim 1 or 2, wherein the pH of the citric acid solution is adjusted by disodium hydrogen phosphate dodecahydrate, preferably, the pH of the citric acid solution is 3.0-3.5, more preferably, the pH of the citric acid solution is 3.2, 3.3, 3.4 or 3.5.
  4. The kit according to any one of claims 1 to 3, wherein the concentration of the citric acid is 0.5 mol/L.
  5. The kit according to any one of claims 1 to 4, wherein the pre-excitation solution is 1% (w/v) hydrogen peroxide solution, and the excitation solution is 1 mol/L sodium hydroxide solution, optionally, the first antibody is 10C11 and the second antibody is 14D9-2.
  6. The kit according to any one of claims 1 to 5, wherein:
    the method for preparing the M reagent comprises: the first antibody and the magnetic particles are mixed in 2-morpholineethanesulfonic acid buffer with pH=5.0∼6.0, coated at 25-37°C for 1-3h, added with 0.1%∼0.5% (w/v) bovine serum albumin phosphate buffer with pH=8.0∼9.0 to perform termination for 1∼3h, the coated magnetic particles are separated and dispersed in a phosphate buffer with pH=7.0∼8.0, then added with 0.04∼0.06% (w/v) surfactant (the surfactant is optionally Tween-20; in one embodiment, the surfactant is 0.05% (w/v) Tween-20) and 8∼12% (w/v) sucrose (optionally, 10% (w/v) sucrose) to obtain the M reagent;
    the method for preparing the R2 reagent comprises: the second antibody and acridinium ester are mixed in a phosphate buffer with pH=8.0∼9.0, coated at 25-37°C for 1∼3h, and then added with a Tris buffer comprising 0.1%∼0.5% (w/v) bovine serum albumin and having pH=8.0∼9.0 to perform termination for 1∼3h so as to obtain a stock solution, and the stock solution is diluted with a phosphate buffer having pH=7.0∼8.0 to 1:100∼500 to obtain the R2 reagent.
  7. The kit according to any one of claims 1 to 6, wherein:
    the method for preparing the luminescent plate coating source comprises: the coated first antibody is diluted with a phosphate buffer having pH=7.0∼8.0 as coating buffer to 100∼500ng/well (optionally, 500ng/well), added to the luminescent plate, 100µL per well, incubated at 37°C for 2h or 4°C overnight, the coating buffer is poured out, 200µL of the blocking solution comprising 5-8% (w/v) calf serum and 0.02% (w/v) sodium azide is used for incubation at 37°C for 2h, the liquid in the wells is poured out, the plate is dried and sealed under vacuum with aluminum film, and stored in a dry place at 4°C;
    the method for preparing the labeling enzyme solution comprises: the second antibody and horseradish peroxidase or alkaline phosphatase in ratio of 1:1 are mixed and labeled and dialyzed in a carbonate buffer with pH=9.6, and the dialysis buffer is replaced every 4 hours and replaced for three times, the enzyme-labeled secondary antibody is collected to be a stock solution, and then the stock solution is diluted with a commercially available enzyme diluent to 1:500 to obtain the labeling enzyme solution.
  8. A method for full-range detection of C-reactive protein, which is performed by using the kit according to any one of claims 1 to 7, comprising:
    (1) 20µL of a sample is taken and added to 100µL of the R1 reagent to treat the sample;
    (2) 50µL of the M reagent is then added and incubated together for 15min;
    (3) after step (2), washing is performed with a phosphate buffer comprising 0.05∼0.08% (w/v) Tween-20, then 50 µL of the R2 reagent is added and incubated for 10 minutes;
    (4) after step (3), washing is performed with a phosphate buffer comprising 0.05∼0.08% (w/v) Tween-20, and 100 µL of the pre-excitation solution is added to perform pre-excitation;
    (5) the pre-excitation solution is removed, 100 µL of the excitation solution is then added to perform excitation and detection.
  9. Use of a citric acid solution as a sample treatment solution in manufacture of a kit for full-range detection of C-reactive protein.
  10. The use according to claim 9, wherein the citric acid solution is a citric acid solution with a concentration of 0.1∼1M, pH=3∼4; preferably, the pH of the citric acid solution is adjusted by disodium hydrogen phosphate dodecahydrate, more preferably, the pH of the citric acid solution is 3.0-3.5, and more preferably, the pH of the citric acid solution is 3.2, 3.3, 3.4 or 3.5.
EP19823488.2A 2018-06-20 2019-05-29 Method for full course detection of c-reactive protein and corresponding kit Active EP3812771B1 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
CN201810634120.5A CN110618263B (en) 2018-06-20 2018-06-20 Method for detecting C-reactive protein in whole process and corresponding kit
PCT/CN2019/089015 WO2019242474A1 (en) 2018-06-20 2019-05-29 Method for full course detection of c-reactive protein and corresponding kit

Publications (3)

Publication Number Publication Date
EP3812771A1 true EP3812771A1 (en) 2021-04-28
EP3812771A4 EP3812771A4 (en) 2022-03-30
EP3812771B1 EP3812771B1 (en) 2023-12-27

Family

ID=68920692

Family Applications (1)

Application Number Title Priority Date Filing Date
EP19823488.2A Active EP3812771B1 (en) 2018-06-20 2019-05-29 Method for full course detection of c-reactive protein and corresponding kit

Country Status (8)

Country Link
US (1) US20210263029A1 (en)
EP (1) EP3812771B1 (en)
JP (1) JP7166364B2 (en)
KR (1) KR102459248B1 (en)
CN (1) CN110618263B (en)
AU (1) AU2019289401B2 (en)
CA (1) CA3103848C (en)
WO (1) WO2019242474A1 (en)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN112051403A (en) * 2020-08-27 2020-12-08 武汉生之源生物科技股份有限公司 C-reactive protein chemiluminescence immunoassay kit and preparation method and application thereof
CN114152755A (en) * 2021-12-06 2022-03-08 石家庄斯巴克生物科技有限公司 C-reactive protein detection reagent treatment solution, kit and detection method
CN114216897A (en) * 2021-12-22 2022-03-22 武汉生之源生物科技股份有限公司 sST2 chemiluminescence detection kit and detection method thereof
CN114544978A (en) * 2022-03-04 2022-05-27 美康生物科技股份有限公司 IGF-1 detection kit, preparation method and detection method thereof
CN116203243A (en) * 2022-09-13 2023-06-02 美康生物科技股份有限公司 PINP monoclonal antibody, kit containing PINP monoclonal antibody and application of PINP monoclonal antibody
CN115975025B (en) * 2022-11-01 2023-06-23 北京中楷健康科技有限公司 C-reactive protein (CRP) detection kit

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5358852A (en) * 1992-12-21 1994-10-25 Eastman Kodak Company Use of calcium in immunoassay for measurement of C-reactive protein
JP2003066047A (en) * 2001-06-14 2003-03-05 Matsushita Electric Ind Co Ltd Immune reaction measuring method and immune reaction measuring reagent used therefor
US7101683B2 (en) * 2001-06-26 2006-09-05 Abbott Laboratories Methods for the simultaneous detection of HCV antigens and HCV antibodies
JPWO2005031353A1 (en) * 2003-09-26 2006-12-07 松下電器産業株式会社 Immune reaction measurement method, and reagent, kit, and optical cell used therefor
CN103562720B (en) 2011-03-28 2016-08-17 美迪恩斯生命科技株式会社 The method of immunity of whole blood sample and mensuration test kit
CN103941017B (en) * 2014-03-18 2016-01-20 北京普恩光德生物科技开发有限公司 C reactive protein detection kit
CN103940992B (en) * 2014-05-08 2016-02-24 北京玖佳宜科技有限公司 C reactive protein detection kit and preparation thereof
CN105988003B (en) * 2015-01-28 2018-06-19 厦门万泰凯瑞生物技术有限公司 A kind of whole process c reactive protein assay kit and its application
CN107402308A (en) * 2017-06-21 2017-11-28 北京科跃中楷生物技术有限公司 Immue quantitative detection reagent boxes of IL 6 and preparation method thereof
CN107656043A (en) * 2017-09-21 2018-02-02 苏州新波生物技术有限公司 A kind of c reactive protein magnetic particle detection kit and its application method
CN107632163A (en) * 2017-10-16 2018-01-26 苏州长光华医生物医学工程有限公司 A kind of detection method of hs-CRP

Also Published As

Publication number Publication date
CN110618263B (en) 2021-10-29
KR20210022692A (en) 2021-03-03
CN110618263A (en) 2019-12-27
US20210263029A1 (en) 2021-08-26
JP2021527824A (en) 2021-10-14
AU2019289401B2 (en) 2022-08-25
KR102459248B1 (en) 2022-10-25
WO2019242474A1 (en) 2019-12-26
CA3103848A1 (en) 2019-12-26
CA3103848C (en) 2024-01-02
AU2019289401A1 (en) 2021-01-14
EP3812771A4 (en) 2022-03-30
EP3812771B1 (en) 2023-12-27
JP7166364B2 (en) 2022-11-07

Similar Documents

Publication Publication Date Title
EP3812771B1 (en) Method for full course detection of c-reactive protein and corresponding kit
Collinson et al. Cardiac troponins in patients with renal dysfunction
CN115128279A (en) Biomarkers for risk assessment and therapy monitoring in heart failure patients guided by natriuretic peptides
JP4562771B2 (en) TIMP-2 as a target / marker of beta cell failure
JP2010513917A (en) Method for measuring plasma levels of long pentraxin PTX3
CN110658344A (en) Markers for statin therapy stratification in heart failure
US20060084126A1 (en) Migration inhibitory factor in serum as a tumor marker for prostate, bladder, breast, ovarian, kidney and lung cancer
CA3086889A1 (en) Reference standard for bnp measurement
JP2024514676A (en) PCT Marker Panel for Early Detection of Sepsis
EP3106466B1 (en) Peptide, magnetic peptide and method for detecting celiac disease
US7138239B2 (en) Method and reagent for testing for multiple organ failure in SIRS by cytochrome C measurement
García-Mancebo et al. Heterophile antibodies produce spuriously elevated concentrations of cardiac Troponin I in patients with Legionella pneumophila
JP3298812B2 (en) Method for measuring urinary trypsin inhibitor
CN113820496A (en) Kit and method for quantitatively detecting human lipopolysaccharide binding protein
JP2024516678A (en) STREM1 Marker Panel for Early Detection of Sepsis
JP2024516679A (en) IGFBP7 Marker Panel for Early Detection of Sepsis
JP2024516001A (en) ESM1 marker panel for early detection of sepsis
JP2024515086A (en) GDF15 Marker Panel for Early Detection of Sepsis
JP2024516680A (en) IL6 Marker Panel for Early Detection of Sepsis
JP2024516681A (en) sFlt1 Marker Panel for Early Detection of Sepsis - Patent application
AU2001280912A1 (en) Apparatus and method for determining the onset and presence of sepsis conditions
Sin et al. Fluorogenic nanocrystals for highly sensitive detection of C-reactive protein
EP1412471A1 (en) Apparatus and method for determining the onset and presence of sepsis conditions
JP2024516665A (en) Presepsin marker panel for early detection of sepsis
JPH08262021A (en) Pyrocypris luciferase-labeled antibody and its preparation

Legal Events

Date Code Title Description
STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE INTERNATIONAL PUBLICATION HAS BEEN MADE

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE INTERNATIONAL PUBLICATION HAS BEEN MADE

PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: REQUEST FOR EXAMINATION WAS MADE

17P Request for examination filed

Effective date: 20210107

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR

AX Request for extension of the european patent

Extension state: BA ME

REG Reference to a national code

Ref country code: HK

Ref legal event code: DE

Ref document number: 40042251

Country of ref document: HK

DAV Request for validation of the european patent (deleted)
DAX Request for extension of the european patent (deleted)
A4 Supplementary search report drawn up and despatched

Effective date: 20220301

RIC1 Information provided on ipc code assigned before grant

Ipc: G01N 33/577 20060101ALI20220224BHEP

Ipc: G01N 33/68 20060101AFI20220224BHEP

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: EXAMINATION IS IN PROGRESS

17Q First examination report despatched

Effective date: 20230111

P01 Opt-out of the competence of the unified patent court (upc) registered

Effective date: 20230628

GRAP Despatch of communication of intention to grant a patent

Free format text: ORIGINAL CODE: EPIDOSNIGR1

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: GRANT OF PATENT IS INTENDED

INTG Intention to grant announced

Effective date: 20230920

GRAS Grant fee paid

Free format text: ORIGINAL CODE: EPIDOSNIGR3

GRAA (expected) grant

Free format text: ORIGINAL CODE: 0009210

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE PATENT HAS BEEN GRANTED

AK Designated contracting states

Kind code of ref document: B1

Designated state(s): AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR

REG Reference to a national code

Ref country code: GB

Ref legal event code: FG4D

REG Reference to a national code

Ref country code: CH

Ref legal event code: EP

REG Reference to a national code

Ref country code: DE

Ref legal event code: R081

Ref document number: 602019044163

Country of ref document: DE

Owner name: XIAMEN UNIVERSITY, XIAMEN, CN

Free format text: FORMER OWNERS: XIAMEN INNOVAX BIOTECH CO., LTD., XIAMEN, FUJIAN, CN; XIAMEN UNIVERSITY, XIAMEN, FUJIAN, CN

Ref country code: DE

Ref legal event code: R081

Ref document number: 602019044163

Country of ref document: DE

Owner name: XIAMEN INNODX BIOTECH CO., LTD, XIAMEN, CN

Free format text: FORMER OWNERS: XIAMEN INNOVAX BIOTECH CO., LTD., XIAMEN, FUJIAN, CN; XIAMEN UNIVERSITY, XIAMEN, FUJIAN, CN

REG Reference to a national code

Ref country code: DE

Ref legal event code: R096

Ref document number: 602019044163

Country of ref document: DE

REG Reference to a national code

Ref country code: IE

Ref legal event code: FG4D

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: GR

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20240328

REG Reference to a national code

Ref country code: LT

Ref legal event code: MG9D

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: LT

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20231227

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: ES

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20231227

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: LT

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20231227

Ref country code: GR

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20240328

Ref country code: FI

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20231227

Ref country code: ES

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20231227

Ref country code: BG

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20240327

REG Reference to a national code

Ref country code: NL

Ref legal event code: MP

Effective date: 20231227